Italian Network for the Improvement of Compliance in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01292499
Recruitment Status : Unknown
Verified December 2010 by Ospedale Amedeo di Savoia.
Recruitment status was:  Recruiting
First Posted : February 9, 2011
Last Update Posted : February 9, 2011
Information provided by:
Ospedale Amedeo di Savoia

Brief Summary:
The RIMAT‐De study (Rete Italiana per il Miglioramento dell'Adesione al Trattamento nella Depressione) is a multicentric Randomized Controlled Clinical Trial aiming at identifying the best strategies available to reduce the poor compliance of patients with antidepressant drugs. Patients' compliance will be measured within six months of pharmacological treatment, comparing the specific contributions of brief psychotherapy and psychoeducational interventions: the psychoeducational intervention will encompass the monitoring of drugs' side effects and patients' satisfaction. In the rest of the document, for the sake of brevity the two treatments previously described will be indicated as "psychotherapy" and "psychoeducation". These treatments will be compared with the treatment usually carried on by the mental health centers involved (i.e. treatment as usual, TAU). The factorial design of the study will take into consideration the combination of the two treatments (i.e. psychotherapy and psychoeducation) as well.

Condition or disease Intervention/treatment Phase
Depression Behavioral: Psychotherapy Behavioral: Psychoeducation Behavioral: Psychoeducation and psychotherapy Not Applicable

Detailed Description:
Another important aim of the study is the investigation of whether the clinical improvement depends on the efficacy of the psychological treatments proposed per se, or whether they just contribute to increase the compliance with the pharmacological treatment, maintaining the patients on treatment longer and allowing the drugs to reach long‐lasting effects. While recognizing the general therapeutic efficacy of psychotherapy in the treatment of depressive disorders, nevertheless the present study aims at verifying whether an equal therapeutic effect may be reached via a better compliance with the pharmacological treatment, fostered for example by the psychoeducational intervention. The rationale lays on the ease of transferability of psychoeducational interventions to the general clinical practice, that usually suffers from lack of resources in implementing structured psychotherapy interventions.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1264 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Italian Network for the Improvement of Compliance in Depression
Study Start Date : March 2009
Estimated Primary Completion Date : January 2012
Estimated Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Pharmacological treatment
Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
Experimental: Psychotherapy
Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4‐6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
Behavioral: Psychotherapy
10 sessions (50 min)

Experimental: Psychoeducation
Will receive psychoeducation as well, with phone monitoring and regular follow‐ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
Behavioral: Psychoeducation
7 sessions + 7 phone calls

Experimental: Psychoeducation and psychotherapy
Will receive both psychoeducation and psychotherapy sessions.
Behavioral: Psychoeducation and psychotherapy
Psychoeducation + psychotherapy

Primary Outcome Measures :
  1. Proportion of patients showing good compliance, as measured at six months from the beginning of the treatment. [ Time Frame: 3 years ]
    The effect size is conceptualized as the difference between the proportion of patients in the 4 treatment arms showing good compliance at the end of the study. The effects of the two treatments (psychotherapy and psychoeducation) will be measured separately, via stratified analyses and multivariate regression models, as appropriate.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. New episode of depression, according to the DSM‐IV (Codes F32 Major Depressive Disorder, single episode; F33 Major Depressive Disorder, recurrent; F34.1 Dysthymic Disorder; F32.9 Depressive Disorder, not otherwise specified), or new contact with the Mental Health Center for recurrent depression (same Codes) after a six‐month period (or longer) without any treatment;
  2. Age >= 18 years old;
  3. QIDS‐SR16 score >=10;
  4. Necessity of a pharmacological antidepressant treatment;
  5. Written informed content given by the participant before the beginning of the study.

Exclusion Criteria:

  1. Comorbidity of schizophrenic disorder, according to the DSM‐IV (Codes F06.3 - Organic mood disorder; F20 - Schizophrenia; F29 -Uunspecified Nonorganic Psychosis; F30‐F31 - Manic Episode and Bipolar Affective Disorder; F34.0 - Cyclothymia; F10‐F19 - Mental and Behavioural Disorders due to Psychoactive Substance Use).
  2. Current pregnancy.
  3. Probable hospitalization, for whatever reason.
  4. Patient seen once and then referred to his/her GP or other specialist physician;
  5. Pharmacological treatment already prescribed by a psychiatry or neurology specialist. However, if the patient is not satisfied with the current treatment and/or the psychiatrist involved in the present study considers appropriate to change the treatment, the present exclusion criterion will not be valid any longer.
  6. Pharmacological treatment prescribed for more than 15 days by patient's GP. However, if the patient is not satisfied by the treatment and/or the psychiatrist involved in the present study considers appropriate to change the treatment, the present exclusion criterion will not be valid any longer.
  7. The patient is currently under psychotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01292499

Contact: Carmine Munizza 00390114395803

ASL TO2 Amedeo di Savoia Recruiting
Torino, Italy, 10149
Contact: Carmine Munizza    00390114395803      
Sponsors and Collaborators
Ospedale Amedeo di Savoia

Responsible Party: Carmine Munizza, Centro Studi e Ricerche in Psichiatria Identifier: NCT01292499     History of Changes
Other Study ID Numbers: RIMAT‐De
First Posted: February 9, 2011    Key Record Dates
Last Update Posted: February 9, 2011
Last Verified: December 2010

Keywords provided by Ospedale Amedeo di Savoia:

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders